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Studies have demonstrated the significant role of cholesterol and lipoprotein metabolism
in the progression of cancer. The SCARB1 gene encodes the scavenger receptor class
B type I (SR-BI), which is an 82-kDa glycoprotein with two transmembrane domains
separated by a large extracellular loop. SR-BI plays an important role in the regulation of
cholesterol exchange between cells and high-density lipoproteins. Accordingly, hepatic
SR-BI has been shown to play an essential role in the regulation of the reverse
cholesterol transport pathway, which promotes the removal and excretion of excess body
cholesterol. In the context of atherosclerosis, SR-BI has been implicated in the regulation
of intracellular signaling, lipid accumulation, foam cell formation, and cellular apoptosis.
Furthermore, since lipid metabolism is a relevant target for cancer treatment, recent
studies have focused on examining the role of SR-BI in this pathology. While signaling
pathways have initially been explored in non-tumoral cells, studies with cancer cells have
now demonstrated SR-BI’s function in tumor progression. In this review, we will discuss
the role of SR-BI during tumor development and malignant progression. In addition,
we will provide insights into the transcriptional and post-transcriptional regulation of the
SCARB1 gene. Overall, studying the role of SR-BI in tumor development and progression
should allow us to gain useful information for the development of new therapeutic
strategies.
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INTRODUCTION
In human, cholesterol is transported by lipoproteins [i.e., low-density lipoproteins (LDL) and high-
density lipoproteins (HDL)], which permit its transfer to tissues. Cholesterol elimination from
the body is performed via the reverse cholesterol transport pathway, which allows the transfer of
peripheral cholesterol to HDL and eventually its transfer to the liver for excretion. Interestingly,
solid tumors have been shown to accumulate greater amounts of cholesterol when compared to
the host healthy tissues (Freeman and Solomon, 2004; Krycer and Brown, 2013; de Gonzalo-Calvo
et al., 2015). Intratumor accumulation of cholesterol appears to be a consequence of both de novo
synthesis and lipoprotein-mediated uptake (de Gonzalo-Calvo et al., 2015; Murai, 2015). In this
mini-review, we will focus on the role of the HDL receptor, the scavenger receptor class B type
I (SR-BI) in the regulation of cholesterol and lipoprotein metabolism in the context of cancer.
Although SR-BI’s contributions to reverse cholesterol transport in cardiovascular diseases have
been extensively studied, recent evidence has suggested that cholesterol and its metabolites may
Gutierrez-Pajares et al. SR-BI, HDL Metabolism and Cancer
play a critical role in cancer progression (Danilo and Frank, 2012;
Silvente-Poirot and Poirot, 2012; Simko and Ginter, 2014; Kuzu
et al., 2016).
SR-BI: INITIAL CHARACTERIZATIONS
SR-BI is a member of the Class B family of Scavenger Receptor
proteins, which also include CD36 Antigen-like2 (LIMPII) and
CD36 (Calvo et al., 1995). These three glycoproteins share
a common structure: two transmembrane domains associated
with two intracellular N- and C-termini and an extracellular
glycosylated central domain. Initially, human SR-BI was termed
CD36 and LIMPII Analogous-1 (CLA-1; Calvo and Vega, 1993)
and was found to be highly expressed in adrenal glands (Liu et al.,
1997), liver and steroidogenic tissues (Calvo et al., 1997). SR-BI is
a receptor for HDL, and it promotes selective HDL-cholesteryl
ester (HDL-CE) uptake by cells without particle uptake (Silver
et al., 2000; Trigatti et al., 2000). Additionally, studies have shown
that SR-BI can also promote the elimination of excess body
cholesterol via billiary cholesterol secretion (Harder et al., 2007;
Wiersma et al., 2009a,b).
SCARB1 GENE LOCALIZATION, SPLICE
VARIANTS, AND PROTEIN DOMAINS
The gene encoding SR-BI has been designated SCARB1. Human
SCARB1 is located on chromosome 12 at q24.31 and comprises
13 exons and 12 introns that span over 86 kb. Due to alternative
splicing sites, several mRNA variants of SCARB1 have been
identified (Webb et al., 1997, 1998). Interestingly, a short variant
containing only the last 2 exons of SCARB1 has been detected
by next-generation sequencing in non-malignant adrenal glands
and livers at relatively high levels (Carithers et al., 2015).
Nevertheless, no experimental data has been reported on the
physiological significance of this finding.
The predicted molecular weight of SR-BI is 56.9 kDa, but
it is frequently detected as an 82 kDa protein after SDS-PAGE
migration due to post-translational glycosylation (Acton et al.,
1994; Babitt et al., 1997). Using SR-BI aminoacid sequence
Q8WTV0-2 (UniProt, 2015), the following main domains
of SR-BI can be identified: Cytoplasmic N-terminal domain
(residues 1–11), transmembrane domain #1 (residues 12–32),
extracellular domain (residues 33–440), transmembrane domain
#2 (residues 441–461), and cytoplasmic C-terminal domain
(residues 462–509). According to the UniProt website (accessed
July 2016, UniProt, 2015), five protein variants may be produced
by alternative splicing of human SCARB1 mRNA: isoform 3
(Q8WTV0-1), the canonical sequence, represents the longest
variant with 552 residues; isoform 1 (Q8WTV0-2), the first
isoform identified and named SR-BI, with 509 residues; isoform
2 (Q8WTV0-3; aka, SR-BII), with 409 residues; isoform 4
(Q8WTV0-2; aka, SR-BIII), with 474 residues; and isoform 5
(Q8WTV0-5), with 506 residues. Isoforms 1, 2, and 4 share
a common C-terminal sequence (468–552 aa) that includes
the VLQEAKL sequence required to bind the PDZ domain-
containing protein (PDZK1), which has also been described in
the mouse sequence (Silver, 2002; Kocher et al., 2010). The
physiological relevance of these variants is not evident but SR-BII
has been shown to display reduced selective cholesteryl ester
uptake efficiency from HDL (Webb et al., 1998). SR-BI isoform
distributionmay also be altered in certain types of cancer (Arenas
et al., 2004), compared to the corresponding healthy tissues, and
it is possible that different SR-BI isoforms may have different
ability to promote cholesterol entry or eﬄux. Therefore, these
isoforms may differently regulate cholesterol homeostasis and/or
signaling pathways involved in tumor progression.
REGULATIONS OF SCARB1
TRANSCRIPTION AND SR-BI PROTEIN
LEVELS
Steroidogenic tissues (Cao et al., 1997; Azhar et al., 2003) and
the liver (Malerød et al., 2002; Huby et al., 2006) present
the highest levels of SCARB1 transcript. Accordingly, a strong
control over transcription of this gene has been recognized.
mRNA transcription of SCARB1 is finely regulated in cells that
perform steroidogenesis, such as the ovaries (Li et al., 1998)
and adrenal glands (Imachi et al., 1999). It has been shown
that the adrenocorticotropic hormone (ACTH), via cAMP, can
stimulate SR-BI expression in human adrenocortical cell lines
and promotes the secretion of aldosterone and cortisol (Imachi
et al., 1999). However, no canonical cAMP responsive element
(CRE) has been found in the promoter of SCARB1 (Towns and
Menon, 2005). This finding suggests that activation via CREB
may occur via non-canonical CRE elements or cAMP regulates
the activity of other transcription factors. Several activators of
SCARB1 transcription have been identified in a variety of cell
types. Activation by Peroxisome proliferator-activated receptors
(PPARα and PPARγ) promotes transcription of SCARB1 in
monocytes and macrophages (Chinetti et al., 2000). Similarly,
activation of theMek1/2/PPARα pathway has been demonstrated
to up-regulate SR-BI (Wood et al., 2011). SREBP-2, which is a
key regulator of cholesterol metabolism, binds SCARB1 promoter
to induce SCARB1 mRNA up-regulation (Tréguier et al., 2004).
LXRα/RXR and LXRβ/RXR have also been shown to induce
SCARB1 transcription in human and murine hepatoma cell
lines and in 3T3-L1 preadipocytes independently of SREBP-1
(Malerød et al., 2002). In agreement with these findings, the
LXR agonist T0901317 but not 22-(R)-hydroxycholesterol has
been shown to induce an up-regulation of SCARB1 mRNA in
endothelial cells (Norata et al., 2005). Finally, 17β-estradiol has
also been shown to transcriptionally up-regulate SR-BI via PKC
activation in vascular endothelial cells (Fukata et al., 2014).
Taken together, these data show that regulation of SCARB1
transcription is strongly controlled by signaling pathways
involved in cellular lipid/cholesterol homestasis. Therefore, it is
not surprising to observe an upregulation of SR-BI in cancer
cells (Table 1), which often display increased cellular cholesterol
levels.
Furthermore, recent studies have also shown that the
proto-oncogene c-Myc may play a role in the regulation of
SCARB1 transcription (Pello et al., 2012). Moreover, in silico
nucleotide analysis of SCARB1 promoter (nucleotide −499 to
100, LASAGNA Search 2.0) shows potential binding sites for
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TABLE 1 | Expression of SR-BI in cancer tissues or cell lines and its association with malignant features.
Type of cancer Type of sample Expression levels (compared to
non-malignant tissue or cells)
Associated with References
Adrenocortical carcinomas Tissue Decreased ND Liu et al., 1997
Testicular seminoma Tissue Decreased ND Arenas et al., 2004
Leydig cell tumor Tissue Increased ND Liu et al., 1997
Breast Tissue Increased ND Cao et al., 2004
Breast Tissue Increased More aggressive tumor type Yuan et al., 2016
Prostate Tissue Increased Increased malignancy and
androgen-independent growth
Schorghofer et al., 2015
Nasopharyngeal carcinoma Tissue Increased ND Zheng et al., 2013
Nasopharyngeal carcinoma Cell line Increased Enhanced cell migration but not proliferation Zheng et al., 2013
Breast Cell line NA Enhanced proliferation Cao et al., 2004
Breast Cell line NA Enhanced proliferation and migration, and
tumor growth in xenograft tumor model
Danilo et al., 2013
Prostate Cell line NA PSA production and cell viability Twiddy et al., 2012
Breast PyMTTg mouse model Increased Tumor growth Llaverias et al., 2011
Prostate TRAMP mouse model Increased Tumor growth Llaverias et al., 2010
ND, not determined; NA, not applicable.
c-Myc, Stat proteins, PPARγ, p53, and NF-κB. Given the role of
transcription factors such as c-Myc, p53, Stat in cancer, additional
studies should be designed to better understand the role of these
transcription factors in the regulation of SR-BI expression in
cancer.
In addition to transcription factors regulating gene expression,
mRNA levels of SCARB1 can also be regulated by microRNAs
(miRNAs), which can bind the 3′-UTR of mRNA. Studies have
shown that miR-125a and miR-455 can reduce both mRNA and
protein levels of SR-BI in steroidogenic cells (Hu et al., 2012).
Similarly, miR-185, -96, and -223 have been shown to decrease
mRNA levels of SCARB1 in HepG2 cells (Wang et al., 2013).
Finally, miR-192 was found to directly target SCARB1 mRNA in
adipocytes (Mysore et al., 2016). Although no data on the role of
these miRNAs in the context of SCARB1 and cancer is available,
recent studies have shown that levels of miR-125a (Guo et al.,
2009; He et al., 2015; Tong et al., 2015; Lee et al., 2016), miR-
455 (Chai et al., 2015; Li et al., 2016), miR-185 (Qu et al., 2013;
Fu et al., 2014; Tang et al., 2014; Li et al., 2015; Zhang et al.,
2015), and miR-192 (Feng et al., 2011; Geng et al., 2014; Sun
et al., 2016) are down-regulated in several types of cancer. These
findings suggest that SCARB1 post-transcriptional regulation
may be altered to promote SR-BI expression in cancer cells.
A post-translational regulation of SR-BI has also been
described. In this case, PDZK1 has been shown to physically
interact with SR-BI via a 7-residue domain present in the
C-terminal domain (Silver, 2002; Kocher et al., 2010). This
interaction was demonstrated to be essential for SR-BI post-
transcriptional stabilization in a tissue-dependent manner
(Kocher et al., 2003) and localization to the plasma membrane of
hepatocytes (Silver, 2002; Kocher et al., 2003) but not relevant for
its selective HDL-CE uptake function (Silver, 2002). Importantly,
phosphorylation of serine 509 of PDZK1 is crucial for SR-BI
stabilization (Nakamura et al., 2005). Despite these findings,
the role of PDZK1 in SR-BI post-translational regulation does
not appear to be required in all cell types. In fact, absence of
PDZK1 does not affect SR-BI levels in murine steroidogenic
tissues (Kocher et al., 2003) and human endothelial cells (Kimura
et al., 2006). Remarkably, recent studies have demonstrated that
PDZK1 expression is correlated with Akt activation in the MCF-
7 breast cancer cell line (Kim et al., 2014). This observation
implies a positive feedback regulation between PI3K/AKT and
SR-BI since PI3K is activated by SR-BI (Kimura et al., 2006).
Alternatively, SR-BI protein levels may be regulated by Mek1/2,
which prevents SR-BI proteosomal degradation in hepatocytes
(Wood et al., 2011). Taken together, these studies highlight the
complex regulation of SCARB1/SR-BI transcription/expression
levels.
SIGNALING PATHWAYS REGULATED BY
SR-BI AND HDL
Few data are currently available concerning the signaling
pathways activated or repressed by SR-BI in cancer cells. We
have previously reported that HDL/SR-BI interaction can activate
both PI3K and Erk1/2 pathways in two breast cancer cell lines
(Danilo et al., 2013). These findings are consistent with results
obtained with endothelial cells (Kimura et al., 2010). Besides,
SR-BI also interacts with PDZK1, and this interaction is required
to mediate eNOS activation and endothelial cell migration.
Interestingly, PDZK1 is not required for HDL binding, SR-BI
plasma membrane localization, nor cholesteryl ester uptake (Zhu
et al., 2008). It has been proposed that PDZK1 is important
for HDL/SR-BI-mediated activation of the PI3K (Kimura et al.,
2006) and c-Src (Zhu et al., 2008) pathways, and stimulation
of migration in endothelial cells (Zhu et al., 2008; Figure 1).
Importantly, activation of this signaling cascade has been shown
to require the interaction of c-Src and SR-BI cytoplasmic
C-terminal domain (Seetharam et al., 2006; Zhu et al., 2008).
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FIGURE 1 | Role of SR-BI in the regulation of cellular signaling
pathways and regulation of its expression in cancer cells. PPARα and/or
PPARγ and SREBP pathways may be activated to promote SCARB1 gene
expression. In addition, as described in macrophages, high levels of glucose
may also contribute to SR-BI up-regulation via pathways that remain to be
identified. Several miRNAs (such as miR-192, -185, -125a, and -455) have
been found to regulate the post-transcriptional expression of SR-BI.
Interestingly, these miRs are down-regulated in several cancers. Once
associated with the plasma membrane, SR-BI contributes to the uptake of
cholesteryl ester (CE) from HDL. A relevant residue in SR-BI for this interaction
is Cys384 (denoted with an orange label). CE may be converted into free
cholesterol (FC) which can be incorporated in the plasma membrane or
organelles (such as mitochondria), stored in lipid droplets (LD), or used as
substrate for steroids and other cholesterol metabolites. The C-terminal
domain of SR-BI (denoted in yellow) interacts with PDZK1, which can activate
PI3-kinase (PI3K) and c-Src pathways to promote proliferation and migration.
Another yet unexplored role of SR-BI is its interaction with apoptotic cells. This
interaction may also contribute to the activation of signaling pathways that
promote malignant features.
Signaling pathways activated by another member of the class
B scavenger receptor, CD36, have also been investigated. The
C-terminal domain of CD36 has been shown to also physically
interact with Src family non-receptor tyrosine kinases (Moore
et al., 2002; Rahaman et al., 2006; Tao et al., 2015) that activates
a cascade of signaling molecules such as MAPK, p38, JNK,
FAK, and GTPases (reviewed in Park, 2014). Conversely, over-
expression of a mutant version of SR-BI (lacking the C-terminal
residues 465 to 509) has been shown to prevent HDL-induced
proliferation in the MCF-7 breast cancer cell line (Cao et al.,
2004). Since MCF-7 endogenously express significant levels of
SR-BI (Danilo et al., 2013), the later finding implies a competitive
effect for the SR-BImutant in bindingHDL and regulating down-
stream signaling pathways. Taken together, these data suggest
a relevant role for the C-terminal domain of SR-BI in cell
proliferation of breast cancer cells.
SR-BI, REGULATION OF CELLULAR
CHOLESTEROL HOMEOSTASIS AND
CANCER
The role of cholesterol in tumor progression has been extensively
studied in the past decade. Cholesterol has been shown
to regulate essential signaling pathways involved in cellular
proliferation, migration, survival, thereby promoting cancer
progression. In that regard, several studies have shown that
plasma membrane cholesterol plays an important role in these
pathways (Zhuang et al., 2005). Furthermore, SR-BI has been
shown to regulate cellular cholesterol homeostasis (Phillips,
2014). While CD36 localization in cholesterol-rich plasma
membrane and interaction with caveolin-1 has clearly been
established (Frank et al., 2002; Ring et al., 2006; Thorne et al.,
2006), contradictory results have been obtained concerning SR-
BI and its interaction with specific plasma membrane domains
and cholesterol. Initial studies by Babitt et al. (1997) have
suggested that SR-BI colocalizes with caveolae and is fatty
acylated in the CHO-ldla7-mSR-BI and Y1-BS1 cell lines. These
findings were confirmed by us using COS-7 (Frank et al., 2002)
but Rhainds et al. found SR-BI in lipid raft membrane domains
devoid of caveolin-1 in HepG2 cells (Rhainds et al., 2004).
However, other studies using WI38[SR-BI] and ACTH-treated
murine adrenal Y1-BS1 cells showed that SR-BI was preferentially
associated with non-detergent-resistant membranes and no
interaction with caveolin-1 was needed to reach the plasma
membrane (Peng et al., 2004). Specific culture conditions or
cell types may explain some of the observed contradictory
results. Nevertheless, the C-terminal transmembrane domain
of SR-BI has been shown to interact with cholesterol, and
this domain may act as a cholesterol-sensing domain, which
function remains to be established (Assanasen et al., 2005).
While we have shown that the downregulation of SR-BI in
breast cancer cell lines is associated with reduced cellular
cholesterol content and reduced tumor aggressivity (Danilo
et al., 2013), it remains to be determined whether SR-BI-
regulated signaling pathways and cholesterol homeostasis can be
uncoupled.
ROLE OF SR-BI IN CANCER
Although no study examining the role for SR-BI in the promotion
of cell transformation has been performed, it has been recognized
that cancer cells can use the HDL/SR-BI pathway to take up
cholesteryl ester and enhance malignant phenotypes (Figure 1;
Danilo et al., 2013; Zheng et al., 2013). As shown inTable 1, SR-BI
expression is up-regulated in Leydig cell tumors, nasopharyngeal
carcinoma, and breast and prostate cancers. Among these
cancers, the role of HDL/SR-BI in breast and prostate cancers
have been the most extensively studied. The breast cancer cell
line HBL-100 can take up cholesteryl ester from apoE-depleted
HDL3 via SR-BI (Pussinen et al., 2000). Additionally, over-
expression of SR-BI can enhance HDL-mediated proliferation of
the breast cancer cell line MCF-7 via the PI3K/AP-1 pathway
(Cao et al., 2004). In further support of a role for HDL/SR-
BI in breast cancer growth, we have also demonstrated that
HDL/SR-BI interaction is required for breast cancer cells to
proliferate and migrate in vitro, and SR-BI promotes the growth
of tumors in vivo (Danilo et al., 2013). Similarly, proliferation
of mesenchymal stem cells is also enhanced by HDL/SR-BI
interaction where MAPK/ERK1/2 and PI3K/AKT pathways have
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been inplicated (Xu et al., 2012). Conversely, down-regulation
of SR-BI in prostate cancer cells (C4-2 and LNCap cell lines)
has been shown to cause a significant reduction in cellular
viability and PSA secretion (Twiddy et al., 2012) and inhibit
cellular motility in a wound-healing assay of nasopharyngeal
cancer cell lines (Zheng et al., 2013). However, studies by Sekine
et al. have shown that SR-BI did not regulate HDL-mediated
proliferation of the PC-3 prostate cancer cell line (Sekine et al.,
2010). Nevertheless, down-regulation of SR-BI has also been
observed in adrenocortical carcinomas and testicular seminoma
(Table 1). The reasons for these differences are not clear but
may involve different requirements for cholesterol uptake by the
tumors. In the later cases, cholesterol levels may not be a rate-
limiting factor for tumor growth. Alternatively, other isoforms
of SR-BI or alternative cholesterol uptake pathways may be
upregulated and allow the maintenance of a “tumor specific
cholesterol homeostasis.”
While SR-BI mediates HDL-CE uptake in hepatocytes, in
peripheral tissues, SR-BI binding to HDL can stimulate a net
exit of cholesterol via cholesterol eﬄux from intracellular stores.
In cancer, eﬄux and influx might be finely regulated to ensure
the maintenance of high levels of intracellular cholesterol within
proliferative cancer cells. The direction of cholesterol flux may
depend on the specific and respective properties of cholesterol
acceptors and cellular plasma membrane. Cholesterol eﬄux
mediated by SR-BI highly correlates with HDL phospholipid
content present in serum (Fournier et al., 1996, 1997). To
further test the role of phospholipid, reconstituted HDL
enriched with phosphatidylcholine or sphingomyelin have
been used to study eﬄux and influx mediated by SR-BI
in CHO cells (Yancey et al., 2000). It was concluded that
sphyngomyelin-enriched HDL enhanced net eﬄux by decreasing
SR-BI-mediated cholesterol influx, whereas phosphatidylcholine
enrichment of HDL increased SR-BI-mediated eﬄux (Yancey
et al., 2000). However, it is currently unknown if the same
mechanisms can regulate cholesterol homeostasis in cancer
cells.
When the concentration of glucose is abnormally elevated
as in diabetes, cholesterol metabolism in macrophages is
impaired (Hayek et al., 2007; Zhou et al., 2008). Interestingly,
a glucose-concentration-dependent increase in SR-BI mRNA
and protein levels has been proposed as an explanation for the
abnormal cholesterol metabolism observed in macrophages and
other cells (Tu and Albers, 2001). Moreover, elevated glucose
concentrations can reduce HDL-mediated cholesterol eﬄux and
increase total macrophage cholesterol levels (Gantman et al.,
2010). Importantly, glucose uptake is remarkably enhanced
in tumors (Cantor and Sabatini, 2012), and previous studies
have demonstrated a pro-proliferative role of glucose in the
regulation of cellular proliferation of cancer cells (Masur et al.,
2011). Since glucose and lipid metabolism are interconnected
(reviewed in (Dang, 2012)), these findings suggest that tumor
cell exposure to glucose may contribute in cancer cells to SR-
BI upregulation that may participate in cancer progression
(Figure 1). Interestingly, HDL has also been shown to regulate
glucose metabolism in various cell types (Siebel et al.,
2015).
DEVELOPMENT OF SR-BI INHIBITORS
SR-BI effect on cholesterol transport has been extensively studied
in cardiovascular diseases. Not surprisingly, pharmacological
drugs that block SR-BI-mediated HDL-CE uptake have been
developed in this particular context. Strategies have been applied
to design new specific compounds to target SR-BI. Using high-
throughput screening (HTS), BLT-1 (block lipid transport 1)
was found to specifically inhibit SR-BI lipid transfer (Nieland
et al., 2002). This inhibitor blocks entry of HDL-CE by targeting
Cys384 in the extracellular domain of SR-BI (Yu et al., 2011).
Importantly, our group has reported that BLT-1 can inhibit SR-
BI-mediated cellular proliferation in breast cancer cells (Danilo
et al., 2013). Another small molecule, ITX5061, has been shown
to increase plasma HDL levels in wild type and human apoA-I
transgenic mice in an SR-BI-dependent manner (Masson et al.,
2009). Around a decade after BLT-1 discovery, new molecules
(ML278, ML279, ML312) were identified by HTS as potent
inhibitors with less deleterious effects than ITX5061 and BLT-
1 (Faloon et al., 2010a,b,c). More recently, using structural
comparative analysis to ITX-5061, a non-absorbable potent
compound inhibiting SR-BI has been identified (Sparks et al.,
2016).
Antibodies against the extracellular domain of SR-BI have
also been developed to prevent HDL binding. Accordingly, a
neutralizing antibody against aminoacids 174–356 of murine SR-
BI can block both HDL binding and selective cholesteryl ester
uptake in murine macrophages (Chen et al., 2000). These new
compounds should bring scientists new tools to investigate the
role of SR-BI in cancer development and permit the identification
of new strategies to inhibit tumor growth and cancer progression.
Recent works have also demonstrated that mimetics of HDL
(a.k.a., nanoparticles) can target cells expressing SR-BI. In these
cases, studies have shown that tumor cells overexpressing SR-BI
could be targeted by nanocomplexes, which may promote the
transfer of lipoprotein-derived cargo content (Zheng et al., 2013;
McMahon et al., 2015; Julovi et al., 2016). While this approach
appears to be efficient, it is important to note that SR-BI is
also present at the surface of important non-tumor cells (e.g.,
hepatocytes, endothelial cells...). Therefore, targeting SR-BI at
the surface of tumor cells will require the development of new
methods allowing the specific targeting of these cell types.
CONCLUSIONS
Additional studies remain to be performed to better establish the
role of SR-BI in cancer. In particular, the role of the different
sub-populations of HDL and of other lipoproteins such as LDL
needs to be better characterized. Moreover, it remains to be
determined whether SR-BI can regulate concommitantly cellular
cholesterol homeostasis and various cellular signaling pathways.
Therefore, the development of new types of SR-BI inhibitors and
the identification of their mechanism of action should provide
new information. Alternatively, the use of SR-BI mutants and/or
SR-BI/CD36 chimeric constructs should also allow us to better
understand the role of SR-BI in cancer.
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